We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

128 hedge funds and large institutions have $766M invested in Acceleron Pharma in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 28

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

2% more funds holding

Funds holding: 125 → 128 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

37% less capital invested

Capital invested by funds: $1.21B → $766M (-$447M)

69% less call options, than puts

Call options by funds: $2.08M | Put options by funds: $6.71M

Holders
128
Holders Change
+3
Holders Change %
+2.4%
% of All Funds
3.41%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
17
Increased
65
Reduced
28
Closed
14
Calls
$2.08M
Puts
$6.71M
Net Calls
-$4.63M
Net Calls Change
+$4.79M

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$22.6M
2
NHAS
Novo Holdings A/S
Denmark
+$19.6M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.6M
4
PA
Perceptive Advisors
New York
+$15.3M
5
State Street
State Street
Massachusetts
+$9.78M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$19.7M
2
Citadel Advisors
Citadel Advisors
Florida
-$6.2M
3
UBS AM
UBS AM
Illinois
-$4.73M
4
CCP
Clough Capital Partners
Massachusetts
-$4.07M
5
SFM
Sphera Funds Management
Israel
-$2.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
51
Sabby Management
Florida
$1.32M +$1.45M +50,000 New
Bank of America
52
Bank of America
North Carolina
$1.17M -$171K -5,882 -12%
MOACM
53
Mutual of America Capital Management
New York
$1.17M +$1.45K +50 +0.1%
CCM
54
Cupps Capital Management
Illinois
$1.15M +$1.21M +41,635 +2,346%
Swiss National Bank
55
Swiss National Bank
Switzerland
$1.11M +$526K +18,100 +70%
AA
56
ALPS Advisors
Colorado
$1.1M -$60.7K -2,087 -5%
TI
57
Telemetry Investments
New York
$1.02M +$889K +30,570 +385%
TA
58
Teachers Advisors
New York
$999K +$168K +5,781 +18%
UBS Group
59
UBS Group
Switzerland
$995K -$161K -5,528 -13%
HLA
60
Hamilton Lane Advisors
Pennsylvania
$987K -$131K -4,488 -11%
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
$946K -$133K -4,582 -11%
Norges Bank
62
Norges Bank
Norway
$918K +$140K +4,800 +16%
American Century Companies
63
American Century Companies
Missouri
$900K -$80.2K -2,757 -7%
BlackRock
64
BlackRock
New York
$889K +$142K +4,887 +17%
EWM
65
Evercore Wealth Management
New York
$864K -$66.9K -2,300 -7%
Invesco
66
Invesco
Georgia
$844K +$930K +31,967 New
ProShare Advisors
67
ProShare Advisors
Maryland
$804K +$15.9K +547 +2%
MIG
68
Mariner Investment Group
New York
$792K +$151K +5,200 +21%
BBA
69
Baker Bros. Advisors
New York
$759K – – –
WMSA
70
Weiss Multi-Strategy Advisers
New York
$726K +$145K +5,000 +22%
AllianceBernstein
71
AllianceBernstein
Tennessee
$680K +$43.6K +1,500 +6%
Millennium Management
72
Millennium Management
New York
$660K -$19.7M -677,177 -96%
UOC
73
UBS O'Connor
Illinois
$660K +$727K +25,000 New
California Public Employees Retirement System
74
California Public Employees Retirement System
California
$644K -$43.6K -1,500 -6%
New York State Common Retirement Fund
75
New York State Common Retirement Fund
New York
$639K +$64K +2,200 +10%
1 2
3
4 5

XLRN Hedge Fund Activity: Q1 2016 in Review

128 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2016, worth a combined $766M — down 37% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new XLRN positions and 14 closed out — a net gain of 3 holders — while 65 added to existing stakes and 28 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $22.6M. The largest seller was Millennium Management, cutting an estimated $19.7M.

  • 128 institutional investors held Acceleron Pharma (XLRN) as of Q1 2016, up from 125 in Q4 2015.
  • Funds reported $766M of Acceleron Pharma stock for Q1 2016, down 37% quarter-over-quarter.
  • 17 funds opened new Acceleron Pharma positions in Q1 2016 and 14 closed out, a net change of +3 holders.
  • The largest Acceleron Pharma buyer in Q1 2016 was Eagle Asset Management, an estimated $22.6M added.
  • The largest Acceleron Pharma seller in Q1 2016 was Millennium Management, an estimated $19.7M sold.

Based on aggregated 13F filings for Q1 2016.